

Here is a statement on Dr. Findling's behalf.

At the time of manuscript submission, I was confident in the accuracy of the information provided and in the interpretation of the study results. However, in light of ongoing scrutiny of Risperdal, I became concerned about the questions raised and if there were errors. I am committed to determining what they may be and to correcting them. Due to the proprietary nature of the study, access to the data needs to be authorized by Janssen, a subsidiary of Johnson & Johnson. I reached out to them to request a complete set of the data so that a comprehensive review of the findings, including a reanalysis of all data by an independent biostatistician, can be conducted. That independent review is currently under way. Based on the findings, we will decide whether the paper warrants full retraction, a partial correction or whether the original findings stand.

And no, he does not know who conducted the peer review of the manuscript.

Best,
Ekaterina Pesheva <[REDACTED]@jhmi.edu>